Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor palbociclib

被引：4
|
作者：
Romagnuolo, Maurizio [1 ,2 ]
Alberti Violetti, Silvia [1 ,2 ]
Riva, Davide [1 ,2 ]
Barberi, Francesco [1 ,2 ]
Moltrasio, Chiara [2 ,3 ]
机构：
[1] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy
[3] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2023年 / 62卷 / 02期
关键词：
D O I：
10.1111/ijd.16356
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E98 / E100
页数：3
相关论文
共 50 条
  • [21] Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
    Stefanie L. Groenland
    Alejandra Martínez-Chávez
    Marloes G. J. van Dongen
    Jos H. Beijnen
    Alfred H. Schinkel
    Alwin D. R. Huitema
    Neeltje Steeghs
    Clinical Pharmacokinetics, 2020, 59 : 1501 - 1520
  • [22] Flavopiridol, a cyclin-dependent kinase inhibitor
    Lansiaux, A
    Bailly, C
    BULLETIN DU CANCER, 2000, 87 (10) : 697 - 701
  • [23] Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes
    Ericson, KK
    Krull, D
    Slomiany, P
    Grossel, MJ
    MOLECULAR CANCER RESEARCH, 2003, 1 (09) : 654 - 664
  • [24] Is Adjuvant Chemotherapy Preceding Cyclin-Dependent Kinase 4/6 Inhibitor Therapy Beneficial?
    Sorscher, Steven
    JOURNAL OF BREAST CANCER, 2024, 27 (04) : 289 - 291
  • [25] Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
    Ouyang, Zhengxiao
    Wang, Sisi
    Zeng, Ming
    Li, Zhihong
    Zhang, Qing
    Wang, Wanchun
    Liu, Tang
    CELL COMMUNICATION AND SIGNALING, 2019, 17 (1)
  • [26] Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma
    Liu, Songlin
    Yuan, Dun
    Li, Yifeng
    Qi, Qi
    Guo, Bingzhong
    Yang, Shun
    Zhou, Jilin
    Xu, Lu
    Chen, Tiange
    Yang, Chenxing
    Liu, Junyu
    Li, Buyan
    Yao, Li
    Jiang, Weixi
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
    Zhengxiao Ouyang
    Sisi Wang
    Ming Zeng
    Zhihong Li
    Qing Zhang
    Wanchun Wang
    Tang Liu
    Cell Communication and Signaling, 17
  • [28] Phase 2 Trial of the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Patients With Retinoblastoma Protein-Expressing Germ Cell Tumors
    Vaughn, David J.
    Hwang, Wei-Ting
    Lal, Priti
    Rosen, Mark A.
    Gallagher, Maryann
    O'Dwyer, Peter J.
    CANCER, 2015, 121 (09) : 1463 - 1468
  • [29] Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor-positive Prostate and Breast Cancers
    Tien, Amy H.
    Sadar, Marianne D.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (02) : 294 - 309
  • [30] Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma
    Malarikova, Diana
    Jorda, Radek
    Dolnikova, Alexandra
    Pokorna, Eva
    Kazantsev, Dmitry
    Havranek, Ondrej
    Helman, Karel
    Klanova, Magdalena
    Strnad, Miroslav
    Trneny, Marek
    Klener, Pavel, Jr.
    BLOOD, 2021, 138
12345